WorldPharmaNews
  • Home
  • Business
  • Research
  • Jobs
  • Events
  • Regulatory
AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

www.astrazeneca.com

AstraZeneca RSS Channel

Filters
List of articles in category AstraZeneca
Title Published Date
Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer 25 September 2018
The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease 17 September 2018
Tezepelumab granted Breakthrough Therapy Designation by US FDA 07 September 2018
Selumetinib granted orphan designation in Europe for neurofibromatosis type 1 09 August 2018
Atacand to be divested to Cheplapharm in Europe 24 July 2018
Update on Phase III clinical trials of lanabecestat for Alzheimer's disease 12 June 2018
AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline 24 May 2018
AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease 11 May 2018
AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets 07 May 2018
Lokelma approved in the EU for the treatment of adults with hyperkalaemia 22 March 2018
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)
  • Boehringer Ingelheim (Canada) Ltd. and IBM Canada announce first of its kind collaboration to integrate blockchain technology into clinical trials
  • Merz delivers double-digit growth in strategic business areas
  • The Union for International Cancer Control and Pfizer announce new phase of global grants initiative supporting metastatic breast cancer patients
  • Merck to expand US biopharmaceutical R&D facility to advance innovative clinical pipeline

Research & Development

  • Researchers develop reversible antiplatelet therapy to fight clotting, cancer metastasis
  • How Viagra puts a brake on a master growth regulator to treat heart disease
  • Nano drops a million times smaller than a teardrop explodes 19th century theory
  • New insight into cell receptors opens the way for tailored cancer drugs
  • New pill can deliver insulin
  • Simple drug combination creates new neurons from neighboring cells
  • Cannabinoid compounds may inhibit growth of colon cancer cells

Conferences & Events

  • eyeforpharma Barcelona Conference, Expo & Awards 2019
  • SMi presents the 2nd Annual Conference: Injectable Drug Delivery 2019
  • 21st Annual Superbugs & Superdrugs Conference
  • SMi Group announces the 10th Annual RNA Therapeutics Conference
  • Pre-Filled Syringes & Injectable Drug Devices Europe 2018
  • Social Media in the Pharmaceutical Industry Conference 2019
  • Lyophilization USA Conference 2018

Regulatory Affairs

  • FDA takes new steps to adopt more modern technologies for improving the security of the drug supply chain
  • FDA takes action against 17 companies for illegally selling products claiming to treat Alzheimer's disease
  • FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder
  • FDA approves first generic Advair Diskus
  • FDA approves first treatment for rare blood disease
  1. You are here:  
  2. Home
  3. AstraZeneca
  4. US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2006 - 2017. All Rights Reserved. WORLD PHARMA JOBS | PharmaNews.eu | eHealthNews.eu | (HEALTH IT) SPACE